Showing 971-980 of 6040 results for "".
Prurigo Nodularis: An Update for Clinicians, Part 1
https://practicaldermatology.com/topics/general-topics/prurigo-nodularis-an-update-for-clinicians-part-1/20507/Here's a look at the diagnosis of an “eczematous” condition with an unclear etiology.Recent Developments
https://practicaldermatology.com/columns/recent-developments/recent-developments-16/23328/How Ironic Is Iconic?
https://practicaldermatology.com/series/editors-message/how-ironic-is-iconic/23859/"Ask Me Anything" Mentorship Session With Dr. Tina Bhutani
https://practicaldermatology.com/programs/practical-dermatology/ask-me-anything-mentorship-session-with-dr-tina-bhutani/39251/Tina Bhutani, MD, MAS, FAAD, describes her career journey and answers various questions from YoungMD Connect members. YoungMD Connect is an editorially independent platform made possible by industry sponsorships. We would like to thank our silver platform sponsor, Incyte, and bronze sponsor, AlmiralContributing Factors to Persistent or Adult-Onset Atopic Dermatitis
https://practicaldermatology.com/programs/dermatology-hub-neuroimmune-network/contributing-factors-to-persistent-or-adult-onset-atopic-dermatitis/48773/Zoe Diana Draelos, MD, discusses potential reasons for the increasing prevalence of atopic dermatitis in adults, especially in certain parts of the world.DermWire TV Extra: 3-Year Clinical Data on Lebrikizumab
https://practicaldermatology.com/series/dermwire-tv/dermwire-tv-extra-3-year-clinical-data-lebrikizumab/28648/Study author Melinda Gooderham, MSc, MD, FRCPC, discusses the new three-year clinical data presented at the European Academy of Dermatology & Venereology (EADV) Congress on the efficacy and safety of lebrikizumab, which the FDA recently approved on September 13 for adults and adolescents with moNIH Analysis Examines Association Between AD and Comorbidities
https://practicaldermatology.com/programs/practical-dermatology-atopic-dermatitis/nih-analysis-examines-association-between-ad-and-comorbidities/27113/In this week's DermwireTV, new NIH data looks at the association between AD and several health conditions; a study evaluates the effect of lebrikizumab monotherapy in patients with moderate-to-severe AD over 16 weeks; and Andrew Mastro provides tips on how to optimize the first 5 minutes with a patiDermWireTV: International Launch of AviClear; Biological Effects of Air Pollution on Human Skin; New AAD Guidelines for Acne Care
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-international-launch-of-aviclear-biological-effects-of-air-pollution-on-human-skin-new-aad-guidelines-for-acne-care/20261/In this episode of DermWireTV, we report on the international launch of the first energy-based device FDA-cleared for the long-term treatment of mild, moderate, and severe acne. An expert discusses a recent study that examines the biological effects of air pollution on human skin equivalents. For thLow-Nickel Diets Show Promise for Contact Dermatitis
https://practicaldermatology.com/conferences/maui-derm-2024/low-nickel-diets-show-promise-for-contact-dermatitis/20256/Matthew Zirwas, MD, discusses his experience with the “low-nickel diet” for patients who have systemic reactions to dietary nickel.Practice Pearls for PDT
https://practicaldermatology.com/series/pdt-in-practice/practice-pearls-for-pdt/20213/Jill S. Waibel, MD a Miami dermatologist specializing in laser surgery, cosmetic dermatology, and medical dermatology, discusses her background in the use of photodynamic therapy (PDT) and provides insight into off-label PDT treatments she provides her patients. Dr. Waibel is a world-recognized lead